



**Methamphetamine Use in HIV-infected Individuals Affects T-cell Function and  
Viral Outcome during Suppressive Antiretroviral Therapy**

Marta Massanella, Sara Gianella, Rachel Schrier, Jennifer Dan, Josué Pérez-Santiago, Michelli F. Oliveira, Douglas D Richman, Susan J Little, Constance A Benson, Eric S Daar, Michael P. Dube, Richard H Haubrich, Davey M Smith and  
Sheldon R. Morris



**Supplementary Figure 1:** Distribution of frequencies and absolute counts of CD8 (Panel A and B) and CD4 (Panel C and D) T-cell subsets in meth-users (orange squares) and control group (blue circles) are plotted. Individual and median values are shown. Two-sided p-values (Mann Whitney U test) are indicated.



**Supplementary Figure 2:** Levels of CD4 T-cell activation (defined as CD38+CD45RA-) are shown in four groups stratified by Meth-usage and CMV shedding status. Individual and median values are shown. Two-sided p-values (Mann Whitney U test) are indicated.

**Supplementary Table 1: Comparison of immune variables between recent meth user and control groups.**

	<b>Meth<sup>1</sup> n=11</b>	<b>Control<sup>1</sup> n=34</b>	<b>P-value<sup>2</sup></b>
<i>Proliferation</i>			
Ki-67 <sup>+</sup> (% of CD4 T cells)	4.3 [3.3-5.0]	3.0 [2.4-4.2]	<b>0.032</b>
Ki-67 <sup>+</sup> (% of Tn CD4 T cells)	2.2 [1.9-5.0]	1.4 [1.0-2.2]	<b>0.021</b>
Ki-67 <sup>+</sup> (% of Tcm CD4 T cells)	4.6 [3.0-5.2]	3.4 [2.5-4.3]	0.12
Ki-67 <sup>+</sup> (% of Ttm CD4 T cells)	4.5 [3.2-4.9]	3.7 [2.6-4.7]	0.28
Ki-67 <sup>+</sup> (% of Tem CD4 T cells)	5.0 [3.8-7.9]	4.1 [2.9-5.5]	0.23
Ki-67 <sup>+</sup> (% of CD8 T cells)	5.9 [3.7-7.1]	2.6 [2.2-3.6]	<b>0.0007</b>
Ki-67 <sup>+</sup> (% of Tn CD8 T cells)	4.4 [2.0-7.0]	1.6 [1.0-2.7]	<b>0.0094</b>
Ki-67 <sup>+</sup> (% of Tcm CD8 T cells)	7.5 [3.8-9.8]	3.1 [2.5-4.8]	<b>0.007</b>
Ki-67 <sup>+</sup> (% of Ttm CD8 T cells)	4.9 [3.1-8.7]	2.6 [2.0-3.5]	<b>0.0054</b>
Ki-67 <sup>+</sup> (% of Tem CD8 T cells)	5.4 [3.9-6.6]	2.6 [2.0-3.7]	<b>0.002</b>
<i>Immune activation</i>			
HLA-DR <sup>+</sup> CD38 <sup>+</sup> (% of CD4 T cells)	3.1 [2.2-5.9]	2.6 [1.9-3.3]	0.28
CD45RA <sup>-</sup> CD38 <sup>+</sup> (% of CD4 T cells)	11.0 [6.9-17.7]	7.0 [5.3-8.7]	<b>0.02</b>
HLA-DR <sup>+</sup> CD45RA <sup>-</sup> (% of CD4 T cells)	8.5 [5.1-19/4]	7.1 [6.1-10.7]	0.28
HLA-DR <sup>+</sup> CD38 <sup>+</sup> (% of CD8 T cells)	12.8 [8.0-21.9]	18.7 [10.0-24.0]	0.45
CD45RA <sup>-</sup> CD38 <sup>+</sup> (% of CD8 T cells)	11.4 [7.5-20.0]	13.2 [5.7-16.6]	0.73
HLA-DR <sup>+</sup> CD45RA <sup>-</sup> (% of CD8 T cells)	18.5 [10.6-28.6]	25.4 [16.7-32.0]	0.16
<i>Exhaustion</i>			
PD-1 <sup>+</sup> (% of CD4 T-cells)	0.6 [0.04-2.9]	0.06 [0.02-0.14]	<b>0.02</b>
PD-1 <sup>+</sup> (% of CD8 T-cells)	0.9 [0.5-1.2]	1.0 [0.5-1.8]	0.7
<i>HIV reservoir</i>			
LogPol (copies/10 <sup>6</sup> cells)	2.1 [1.8-2.6]	1.9 [1.1-2.2]	0.18

<sup>1</sup>Median [IQR] are shown. <sup>2</sup>Mann Whitney U test between meth and non-meth users